- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Nivolumab/CCRT Followed by Nivolumab/Ipilimumab Misses PFS End Point in Select Stage III NSCLC
December 23rd 2024, 2:00pm
CheckMate 73L missed its primary end point of PFS in advanced unresectable stage III non–small cell lung cancer.
Perioperative Pembrolizumab Regimen Upholds Survival Benefit in Resectable NSCLC
December 21st 2024, 11:00am
The neoadjuvant/adjuvant pembrolizumab and chemotherapy combination was approved by the FDA in October 2023 for use in this patient population.
Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC
December 20th 2024, 1:00pm
Zongertinib demonstrated durable efficacy in patients with pretreated advanced HER2-mutant non–small cell lung cancer.
Lenvatinib Shows Efficacy in Advanced HCC Post-Progression on Atezolizumab/Bevacizumab
December 19th 2024, 7:00pm
Second-line lenvatinib had clinically meaningful efficacy in patients with advanced HCC after progression on atezolizumab plus bevacizumab.
Sacituzumab Govitecan Does Not Significantly Improve OS in Pretreated Urothelial Carcinoma
December 19th 2024, 6:00pm
The phase 3 TROPiCS-04 study missed its primary end point of improved OS with sacituzumab govitecan vs chemotherapy in patients with urothelial cancer.
Active Monitoring Is Noninferior to Guideline Concordant Care in Low-Risk DCIS
December 17th 2024, 1:00pm
San Antonio Breast Cancer Symposium
Rates of invasive cancer were noninferior when patients with low-risk ductal carcinoma in situ received active monitoring vs guideline concordant care.
Postoperative Radiation Therapy Improves HRQOL, Safety in Early-Stage HR+/HER2– Breast Cancer
December 16th 2024, 2:00pm
San Antonio Breast Cancer Symposium
Radiation therapy produced superior HRQOL outcomes and fewer toxicities vs endocrine therapy in older patients with stage I luminal-like breast cancer.
Baseline ctDNA Is Associated With Larger Pathological Tumors in HR+ Early Breast Cancer
December 16th 2024, 1:00pm
San Antonio Breast Cancer Symposium
Ultra-sensitive tissue-free ctDNA testing showed that baseline ctDNA was associated with larger pathological tumor size in HR-positive breast cancer.
Elacestrant Improves Real-World Time to Next Treatment or Treatment Discontinuation in ESR1+ HR+/HER2– Breast Cancer
December 15th 2024, 11:00am
San Antonio Breast Cancer Symposium
Elacestrant increased real-world TTNT for patients with ESR1-mutant HR-positive/HER2-negative breast cancer vs PFS from the phase 3 EMERALD trial.
ICIs Result in Increased Rates of High-Grade irAEs for Older Patients With Breast Cancer
December 14th 2024, 11:00am
San Antonio Breast Cancer Symposium
The risk of developing high-grade immune-related AEs was heightened among patients with breast cancer who were older and who had chronic kidney disease.
Dr Grinshpun on Ultra-Sensitive ctDNA Detection in HR+ Early Breast Cancer
December 14th 2024, 12:25am
San Antonio Breast Cancer Symposium
Albert Grinshpun, MD, MSc, discusses the utility of ctDNA as a predictive biomarker of endocrine therapy sensitivity in patients with HR+ breast cancer.
Dr Mayer on Niraparib Plus Dostarlimab in ER+ BRCA/PALB2-Mutated Breast Cancer
December 14th 2024, 12:05am
San Antonio Breast Cancer Symposium
Erica L. Mayer, MD, MPH, discusses findings with neoadjuvant niraparib plus dostarlimab in ER-positive, HER2-negative, BRCA/PALB2-mutated breast cancer.
Recurrence-Free Interval Is Longer With Low ctDNA Levels at Baseline in TNBC
December 13th 2024, 9:48pm
San Antonio Breast Cancer Symposium
ctDNA was most frequently detected within 6 months post-treatment in patients with TNBC, aligning with the early recurrence pattern characteristic of the disease.
Perioperative Atezolizumab Plus Chemo Does Not Improve EFS in TNBC
December 13th 2024, 9:21pm
San Antonio Breast Cancer Symposium
Treatment with atezolizumab and neoadjuvant chemotherapy followed by adjuvant atezolizumab did not improve EFS in triple-negative breast cancer.
T-DXd Preserves QOL, Neurological Function in HER2+ Metastatic Breast Cancer Irrespective of Brain Metastases
December 13th 2024, 9:15pm
San Antonio Breast Cancer Symposium
T-DXd displayed favorable HRQOL and neurological function results in HER2+ metastatic breast cancer regardless of the presence of brain metastases.
Neoadjuvant Niraparib Plus Dostarlimab Generates pCRs in BRCA+ ER+/HER2– Breast Cancer
December 13th 2024, 9:08pm
San Antonio Breast Cancer Symposium
Treatment with preoperative niraparib plus dostarlimab generated responses among patients with BRCA-mutant, ER-positive, HER2-negative breast cancer
Camrelizumab/Chemo Could Represent New Neoadjuvant Option in Early or Locally Advanced TNBC
December 13th 2024, 7:13pm
San Antonio Breast Cancer Symposium
Neoadjuvant camrelizumab paired with chemotherapy significantly improved pCR over chemotherapy alone in early or locally advanced TNBC.
Wrapping up the Pivotal Highlights From SABCS 2024 With Drs Bora Lim and Stephanie Graff
December 13th 2024, 4:42pm
OncLive News Network: On Location at SABCS 2024
Bora Lim, MD, of The University of Texas MD Anderson Cancer, and Stephanie Graff, MD, of Brown University Health, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in breast cancer presented during the 2024 San Antonio Breast Cancer Symposium.
100-mg Bezuclastinib Improves Symptoms, Biomarkers in Non-Advanced Systemic Mastocytosis
December 13th 2024, 3:02pm
ASH Annual Meeting and Exposition
Treatment with a 100-mg dose of bezuclastinib had a favorable safety and tolerability profile in patients with non-advanced systemic mastocytosis.
Dr Rozenblit on Pembrolizumab Outcomes by TMB Status in HR+ Metastatic Breast Cancer
December 13th 2024, 3:10am
San Antonio Breast Cancer Symposium
Mariya Rozenblit, MD, discusses how genomic alterations and TMB influence the efficacy of immune checkpoint inhibitors in HR+ metastatic breast cancer.